2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3072

Childhood Takayasu Arteritis. a Single Center Experience
Abstract Number: 2482

Choosing Subserologies More Wisely: Implementing Anti-Nuclear Antibody (ANA) Reflex Testing and Education to Reduce Unnecessary Costs in an Integrated Healthcare System
Abstract Number: 386

Chronic Arthritis in Systemic Lupus Erythematosus: Distinct Features in 336 Pediatric and 1,830 Adult Patients
Abstract Number: 917

Chronic Widespread Pain in Adolescents Is Highly Associated to Stress and Anxiety
Abstract Number: 3236

Circulating Cytokine/Chemokine Concentrations Predict Cancer Mortality in Men with Rheumatoid Arthritis
Abstract Number: 817

Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus
Abstract Number: 770

Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Abstract Number: 217

Circulating Levels of Neo-Epitopes Reflecting Connective Tissue Turnover As Biomarkers of Gout and Frequent Gout Attacks in Men
Abstract Number: 3195

Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial
Abstract Number: 1880

Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases.
Abstract Number: 2005

Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Abstract Number: 2611

Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Abstract Number: 1100

Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization
Abstract Number: 905

Citrullinated Epithelial-Derived Neutrophil-Activating Peptide 78 (ENA-78/CXCL5) Induces Monocyte Migration Via JNK and NFκB Signaling Pathways
Abstract Number: 526

Citrullinated Fibrinogen Promotes Bone Marrow Mesenchymal Stem Cells to Assume a Proinflammatory Phenotype

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].